Albuquerque's Indica Labs Inc. announced Tuesday it is pairing its technology with a Seoul, South Korea-based medical software company to streamline prostate cancer diagnoses.
The partnership will bring Deep Bio's DeepDX prostate algorithm into Indica Labs' HALO AP platform, which is used as a case and image management solution for pathology.
Deep Bio's DeepDX algorithm uses AI to detect prostate cancer and its severity by analyzing needle biopsies.
Bringing DeepDX onto the HALO AP platform will improve workflows and remove the need to shift between systems, according to a news release.
Deep Bio CEO Sun Woo Kim said in a statement the partnership will lead to better treatment decision-making.
"The integration between DeepDx and HALO AP demonstrates how any algorithm vendor can leverage HALO AP to deliver clinically relevant results directly within the pathologists' viewing software, eliminating the need for an AI-specific viewer," Indica Labs CEO Steven Hashagen said in a statement.
Indica Labs was founded in 2011 and operates out of a 14,500-square-foot facility located at 8700 Education Place NW. In April, the company received a $422,054 Jobs Training Incentive Program grant to train 17 employees and six interns.
